{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=patch&page=77",
    "query": {
      "intervention": "patch",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 3580,
    "total_pages": 358,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=patch&page=78&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=patch&page=76&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T00:09:31.845Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05727839",
      "title": "Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Tumor",
        "Malignant Solid Tumor"
      ],
      "interventions": [
        {
          "name": "JCXH-211 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immorna Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2023-02-24",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05727839"
    },
    {
      "nct_id": "NCT00304239",
      "title": "Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "Metvix-PDT",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Vehicle-PDT",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2006-03-13",
      "completion_date": "2007-01-23",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 4,
      "location_summary": "Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more",
      "locations": [
        {
          "city": "Naperville",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304239"
    },
    {
      "nct_id": "NCT03602339",
      "title": "Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Magnetic Resonance Imaging"
      ],
      "interventions": [
        {
          "name": "Gadoterate (Dotarem/Clariscan)",
          "type": "DRUG"
        },
        {
          "name": "Gadobutrol (Gadavist/Gadovist, BAY86-4875)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2018-11-14",
      "completion_date": "2020-05-26",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602339"
    },
    {
      "nct_id": "NCT06161675",
      "title": "Feasibility of Delivering VergeRx at FQHCs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Tobacco Use Cessation"
      ],
      "interventions": [
        {
          "name": "QuitAid",
          "type": "BEHAVIORAL"
        },
        {
          "name": "SmokefreeTXT",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Nicotine Replacement Therapy Patch",
          "type": "DRUG"
        },
        {
          "name": "Nicotine lozenge",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-09-23",
      "completion_date": "2026-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161675"
    },
    {
      "nct_id": "NCT03112226",
      "title": "Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognitive Impairment",
        "Estrogen Deficiency",
        "Menopause",
        "Endothelial Dysfunction",
        "Vascular Stiffness"
      ],
      "interventions": [
        {
          "name": "GnRHant + E2",
          "type": "OTHER"
        },
        {
          "name": "GnRHant + Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 19,
      "start_date": "2018-02-07",
      "completion_date": "2020-06-21",
      "has_results": false,
      "last_update_posted_date": "2021-06-07",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boulder, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03112226"
    },
    {
      "nct_id": "NCT00499083",
      "title": "Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "therapeutic autologous dendritic cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aromatase inhibition therapy",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "neoadjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "120 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 120 Years · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2006-05-01",
      "completion_date": "2010-01-28",
      "has_results": true,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Omaha, Nebraska",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499083"
    },
    {
      "nct_id": "NCT03398694",
      "title": "Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Radiosurgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2018-03-26",
      "completion_date": "2024-05-21",
      "has_results": false,
      "last_update_posted_date": "2024-07-16",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398694"
    },
    {
      "nct_id": "NCT00605956",
      "title": "NatrOVA Photoallergy Study - NatrOVA Creme Rinse in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head Lice"
      ],
      "interventions": [
        {
          "name": "NatrOVA Creme Rinse - 1%",
          "type": "DRUG"
        },
        {
          "name": "NatrOVA Creme Rinse Vehicle Only",
          "type": "DRUG"
        },
        {
          "name": "Blank Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ParaPRO LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2008-01",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-08-04",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00605956"
    },
    {
      "nct_id": "NCT00791856",
      "title": "Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "testosterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 70 Years · Female only"
      },
      "enrollment_count": 110,
      "start_date": "2007-07",
      "completion_date": "2008-05",
      "has_results": false,
      "last_update_posted_date": "2013-04-17",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 4,
      "location_summary": "Fort Myers, Florida • Miramar, Florida • Overland Park, Kansas + 1 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00791856"
    },
    {
      "nct_id": "NCT03452293",
      "title": "SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PAD"
      ],
      "interventions": [
        {
          "name": "Stent Peripheral System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EndoCore Lab s.r.l.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2018-03-07",
      "completion_date": "2022-03-28",
      "has_results": false,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-11-07T00:09:31.845Z",
      "location_count": 1,
      "location_summary": "Wyoming, Michigan",
      "locations": [
        {
          "city": "Wyoming",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03452293"
    }
  ]
}